0001209191-20-064518.txt : 20201218 0001209191-20-064518.hdr.sgml : 20201218 20201218190217 ACCESSION NUMBER: 0001209191-20-064518 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201130 FILED AS OF DATE: 20201218 DATE AS OF CHANGE: 20201218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BJERKHOLT ERIC CENTRAL INDEX KEY: 0001197350 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 201401971 MAIL ADDRESS: STREET 1: 132 PURDURE AVENUE CITY: KENGSINGTON STATE: CA ZIP: 94708 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1600 FAIRVIEW AVE E. CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-485-7051 MAIL ADDRESS: STREET 1: 1600 FAIRVIEW AVE E. CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH, INC. DATE OF NAME CHANGE: 20111107 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-30 0 0001435049 CHINOOK THERAPEUTICS, INC. KDNY 0001197350 BJERKHOLT ERIC C/O CHINOOK THERAPEUTICS, INC. 1600 FAIRVIEW AVE. E. SEATTLE WA 98102 0 1 0 0 Chief Financial Officer Employee Stock Option (right to buy) 13.98 2020-11-30 4 A 0 144787 0.00 A 2030-11-29 Common Stock 144787 144787 D Restricted Stock Units 2020-11-30 4 A 0 49243 0.00 A Common Stock 49243 49243 D The stock option vests as to 25% of the total shares on November 30, 2021, and thereafter vests as to 1/36 of the remaining shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each restricted stock unit ("RSUs") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as to 33.33% of the total shares on November 30, 2021, and thereafter vests as to 33.33% of the total RSUs on November 30, 2022, and as to 33.33% of the total RSUs on November 30, 2023, subject to the provision of services to the Company on each vesting date. /s/ Kirk Schumacher, Attorney-in-Fact 2020-12-18